Improving Myeloma Outcomes

Ajai Chari, MD

Video Categories: Hematological Malignancies

Dr. Ajai Chari discusses the ultimate goal of improving therapy for myeloma patients. He mentions the COMPASS study, which is working to collect a database of clinical and scientific information on 1000 patients. In the interim, there are some clues, such as an understanding of certain high-molecular-risk patients and some evidence of certain subgroups that have increased response to some new drugs. This allows physicians to be more selective for those who are most likely to benefit from certain therapies.
August 15, 2013

The Evolving Role of Genotypic Data

Dr. Mesa recognizes that although genotypic data is not yet being used to select treatment choice or dosing in myelofibrosis, it is used to address the issues of prognosis and burden of disease.

October 8, 2014

Importance of Cytoreductive Therapy

Laura C. Michaelis, MD, Medical College of Wisconsin describes why cytoreductive therapy is important to discuss with patients with polycthemia vera.Supported through funding from Incyte